Bon Natural Life Limited

BON

$1.13

-1.08%

N/A-$0.01

Basic Materials

Chemicals - Specialty

NASDAQ

Active Trading

Bon Natural Life Limited, accompanied by its various subsidiaries, focuses on the innovation, production, and worldwide distribution of active functional compounds sourced ...

Fundamental Analysis of BON

Key Strengths

Diversified application footprint across personal care, functional foods, and nutritional/supplement markets reduces reliance on a single end demand stream

Specialty focus on active functional compounds and plant-extract-based ingredients can support differentiation versus generic commodity chemicals

Risk Factors

Sustained profitability losses: net margin about -10.7% and operating margin about -8.7% (negative returns on equity/asset)

Negative free cash flow and weak operating cash flow conversion, increasing the likelihood of financing or working-capital restructuring needs

Profitability

Net Margin-10.68%

Operating Margin-8.69%

Valuation

P/E Ratio-4.90x

Current Ratio1.74

Efficiency

ROE-3.59%

ROA-2.34%

Fundamental Analysis of BON

Bon Natural Life Limited (NASDAQ: BON) operates in specialty chemicals/functional natural ingredients, developing and producing active functional compounds from plant extracts for global customers across personal care (fragrance/perfume ingredients), functional foods, and nutritional/health-related applications. The company’s core thesis is diversification of natural-derived ingredients into multiple end markets, supported by R&D and manufacturing capability. However, the most recent TTM fundamentals show significant financial underperformance, which materially constrains valuation support based on earnings and cash flows. Profitability is weak and negative: net margin is about -10.7%, operating margin about -8.7%, and EBITDA margin is roughly 0.1% (nearly breakeven at the EBITDA line but still not translating into positive net income). Returns are also negative—ROE approximately -3.6% and ROA approximately -2.3%—indicating limited ability to generate shareholder and asset value under current operating conditions. Cash flow quality appears poor: free cash flow is negative (free cash flow to firm and to equity are both materially negative), and cash conversion is stretched (cash conversion cycle ~512 days with long inventory and DSO), implying working-capital strain and potential pressure on liquidity. Balance-sheet liquidity is mixed but not alarming: current ratio is ~1.74 and quick ratio ~1.01, suggesting short-term obligations may be manageable, while leverage is modest on a debt-to-equity basis (~0.21). Still, interest coverage is negative (interest coverage about -4.4), consistent with operating weakness and earnings losses. Growth metrics from the provided dataset are not available, and consensus “momentum” appears weak in third-party summaries. Valuation appears optically low on price-to-sales (~0.37) and price-to-book (~0.055), but traditional earnings-based multiples are distorted by negative earnings (P/E is negative). For long-term investors, the key fundamental question is whether management can improve margins, shorten the operating cycle, and produce durable positive free cash flow. Until profitability and cash generation normalize, the risk/reward profile remains skewed toward execution risk rather than valuation support.

Key Strengths of BON

Diversified application footprint across personal care, functional foods, and nutritional/supplement markets reduces reliance on a single end demand stream
Specialty focus on active functional compounds and plant-extract-based ingredients can support differentiation versus generic commodity chemicals
Reasonable short-term liquidity (current ratio ~1.74) can provide operating flexibility during periods of margin pressure
Ongoing R&D investment intensity (R&D/revenue ~0.04) supports the product-innovation pathway for specialty ingredients
Low reported debt burden versus assets/capital (debt-to-equity ~0.21) lowers balance-sheet solvency risk relative to highly levered peers
Attractive headline valuation on sales and book value (P/S ~0.37; P/B ~0.055), which may provide upside if earnings normalize

Risk Factors of BON

Sustained profitability losses: net margin about -10.7% and operating margin about -8.7% (negative returns on equity/asset)
Negative free cash flow and weak operating cash flow conversion, increasing the likelihood of financing or working-capital restructuring needs
Working-capital/cash conversion deterioration (cash conversion cycle ~512 days; high days of inventory and receivables), which can amplify liquidity stress
Interest coverage is negative (about -4.4), indicating that earnings are insufficient to comfortably service interest costs under current conditions
Industry and macro sensitivity: natural ingredients businesses can be affected by raw material cost volatility, regulatory changes, and import/export dynamics
Small-cap execution and commercial risks (limited scale; only ~96 employees reported), which can make revenue growth and margin expansion difficult
Valuation may be a “value trap” risk: low multiples coexist with negative earnings and weak cash generation
Third-party sentiment indicators suggest weak growth/momentum characteristics, implying elevated uncertainty around near-term trajectory

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$6.86M

-4.9x

P/E Ratio

0.4x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin20.77%

Net Profit Margin-10.68%

Debt/Equity Ratio0.21

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of BON

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of BON

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	-20.18%	—	—	Flat
Operating Margin	—	-17.79%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of BON

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	1.739	—	—	Flat
Quick Ratio	—	1.008	—	—	Flat
Debt / Equity	—	0.214	—	—	Flat

Valuation of BON

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-0.62x	—	—	Flat
P/B	—	0.09x	—	—	Flat

Supply Chain of BON

RELATIONS

Upstream

Shaanxi Province Agricultural Herb Cooperatives & Farmers NetworkLocal Chemical & Solvent Suppliers (Xi'an region)Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd.Regional Agricultural Input Suppliers (Shaanxi)

Downstream

Beijing Huahai Keyuan Technology Co., Ltd.Shanghai Yunsheng International Trade Co., Ltd.Shanghai Risesun International Trade Co., Ltd.Tianjin Merrill-Youli Trading Co., Ltd.Shaanxi Qingshengyuan Health Industry Co., Ltd.Guangdong JUWO Trading Co., Ltd.Guangdong Jiangwang International Holdings Inc.OTCPK:JWGJTigerbone Group LimitedPerfume & Fragrance Manufacturers (Asia-Pacific, Europe)Functional Food & Beverage Manufacturers (China, International)

Proxies

Guilin Layn Natural Ingredients Corp.SZSE:002166Chenguang Biotech Group Co., Ltd.SZSE:300138International Flavors & Fragrances Inc.NYSE:IFF

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer